Paraneoplastic pemphigus: A trait d’union between dermatology and oncology
Abstract
Keywords
Full Text:
PDFReferences
Anhalt GJ, Kim SC, Stanley JR, et al. Paraneoplastic pemphigus. An autoimmune mucocutaneous disease associated with neoplasia. N Engl J Med 1990; 323(25): 1729–1735. doi: 10.1056/NEJM199012203232503
Sehgal VN, Srivastava G. Paraneoplastic pemphigus/paraneoplastic autoimmune multiorgan syndrome. Int J Dermatol 2009; 48(2): 162–169. doi: 10.1111/j.1365-4632.2009.03995.x
Nguyen VT, Ndoye A, Bassler KD, et al. Classification, clinical manifestations, and immunopathological mechanisms of the epithelial variant of paraneoplastic auto-immune multiorgan syndrome: a reappraisal of paraneoplastic pemphigus. Arch Dermatol 2001; 137(2): 193–206.
Anhalt GJ. Paraneoplastic pemphigus. J Invest Dermatol Symp Proc 2004; 9(1): 29–33. doi: 10.1111/j.1087-0024.2004.00832.x
Vassileva S, Drenovska K, Manuelyan K. Autoimmune blistering dermatoses as systemic diseases. Clin Dermatol 2014; 32(3): 364–375. doi: 10.1016/j.clindermatol.2013.11.003
Czernik A, Camilleri M, Pittelkow MR, et al. Paraneoplastic autoimmune multiorgan syndrome: 20 years after. Int J Dermatol 2011; 50(8): 905–914. doi: 10.1111/j.1365-4632.2011.04868.x
Ogawa H, Sakuma M, Morioka S, et al. The incidence of external malignancies in pemphigus and bullous pemphigoid in Japan. J Dermatol Sci 1995; 9(2): 135–141. doi: 10.1016/0923-1811(94)00371-K
Cervini AB, Tosi V, Kim SH, et al. Paraneoplastic pemphigus or paraneoplastic autoimmune multiorgan syndrome. Report of 2 cases in children and a review of the literature. Actas Dermosifiliogr 2010; 101(10): 879–886. doi: 10.1016/j.ad.2010.06.012
Mimouni D, Anhalt GJ, Lazarova Z, et al. Paraneoplastic pemphigus in children and adolescents. Br J Dermatol 2002; 147(4): 725–732. doi: 10.1046/j.1365-2133.2002.04992.x
Lane JE, Woody C, Davis LS, et al. Paraneoplastic autoimmune multiorgan syndrome (paraneoplastic pemphigus) in a child: case report and review of the literature. Pediatrics 2004; 114(4): 513–516. doi: 10.1542/peds.2004-0436
Yong AA, Tey HL. Paraneoplastic pemphigus. Australas J Dermatol 2013; 54(4): 241–250. doi: 10.1111/j.1440-0960.2012.00921.x
Bowen GM, Peters NT, Fivenson DP, et al. Lichenoid dermatitis in paraneoplastic pemphigus: a pathogenic trigger of epitope spreading? Arch Dermatol 2000; 136(5): 652–656. doi: 10.1001/archderm.136.5.652
Matz H, Milner Y, Frusic-Zlotkin M, et al. Paraneoplastic pemphigus associated with pancreatic carcinoma. Acta Derm Venereol 1997; 77(4): 289–291.
Wong KC, Ho KK. Pemphigus with pemphigoid-like presentation, associated with squamous cell carcinoma of the tongue. Australas J Dermatol 2000; 41(3): 178–180. doi: 10.1046/j.1440-0960.2000.00434.x
Lee IJ, Kim SC, Kim HS, et al. Paraneoplastic pemphigus associated with follicular dendritic cell sarcoma arising from Castleman’s tumor. J Am Acad Dermatol 1999; 40(2 Pt 2): 294–297. doi: 10.1016/S0190-9622(99)70468-8
VanderWaal RI, Pas HH, Anhalt GJ, et al. PNP as the presenting symptom of lymphoma of the tongue. Oral Oncol 1998; 34(6): 567–570. doi: 10.1016/S1368-8375(98)00020-7
Schaeppi H, Bauer JW, Hametner R, et al. Localized variant of paraneoplastic pemphigus: acantholysis associated with malignant melanoma. Br J Dermatol 2001; 144(6): 1249–1254. doi: 10.1046/j.1365-2133.2001.04243.x
Bazarbachi A, Bachelez H, Dehen L, et al. Lethal paraneoplastic pemphigus following treatment of chronic lymphocytic leukaemia with fludarabine. Ann Oncol 1995; 6(7): 730–731.
Anhalt GJ. Paraneoplastic pemphigus: the role of tumours and drugs. Br J Dermatol 2001; 144(6): 1102–1104. doi: 10.1046/j.1365-2133.2001.04272.x
Lee MS, Kossard S, Ho KK, et al. Paraneoplastic pemphigus triggered by radiotherapy. Australas J Dermatol 1995; 36(4): 206–210. doi: 10.1111/j.1440-0960.1995.tb00976.x
Martel P, Loiseau P, Joly P, et al. Paraneoplastic pemphigus is associated with the DRB1*03 allele. J Autoimmun 2003; 20(1): 91–95. doi: 10.1016/S0896-8411(02)00092-6
Liu Q, Bu DF, Li D, et al. Genotyping of HLA-I and HLA-II alleles in Chinese patients with paraneoplastic pemphigus. Br J Dermatol 2008; 158(3): 587–591. doi: 10.1111/j.1365-2133.2007.08361.x
Kiyokawa C, Ruhrberg C, Nie Z, et al. Envoplakin and periplakin are components of the paraneoplastic pemphigus antigen complex. J Invest Dermatol 1998; 111(6): 1236–1238. doi: 10.1046/j.1523-1747.1998.00449.x
Kim SC, Kwon YD, Lee IJ, et al. cDNA cloning of the 210-kDa paraneoplastic pemphigus antigen reveals that envoplakin is a component of the antigen complex. J Invest Dermatol 1997; 109(3): 365–369. doi: 10.1111/1523-1747.ep12336235
Oursler JR, Labib RS, Ariss-Abdo L, et al. Human auto-antibodies against desmoplakins in paraneoplastic pemphigus. J Clin Invest 1992; 89(6): 1775–1782. doi: 10.1172/JCI115781
Borradori L, Trueb RM, Jaunin F, et al. Autoantibodies from a patient with paraneoplastic pemphigus bind periplakin, a novel member of the plakin family. J Invest Dermatol 1998; 111(2): 338–340. doi: 10.1046/j.1523-1747.1998.00280.x
Lambert J, Bracke S, van Roy F, et al. Serum plakophilin-3 autoreactivity in paraneoplastic pemphigus. Br J Dermatol 2010; 163(3): 630–632. doi: 10.1111/j.1365-2133.2010.09845.x
Brandt O, Rafei D, Podstawa E, et al. Differential IgG recognition of desmoglein 3 by paraneoplastic pemphigus and pemphigus vulgaris sera. J Invest Dermatol 2012; 132(6): 1738–1741. doi: 10.1038/jid.2012.1
Amagai M, Nishikawa T, Nousari HC, et al. Antibodies against desmoglein 3 (pemphigus vulgaris antigen) are present in sera from patients with paraneoplastic pemphigus and cause acantholysis in vivo in neonatal mice. J Clin Invest 1998; 102(4): 775–782. doi: 10.1172/JCI3647
Zimmermann J, Bahmer F, Rose C, et al. Clinical and immunopathological spectrum of paraneoplastic pemphigus. J Dtsch Dermatol Ges 2010; 8(8): 598–606. doi: 10.1111/j.1610-0387.2010.07380.x
Numata S, Teye K, Tsuruta D, et al. Anti-alpha-2-macroglobulin-like-1 autoantibodies are detected frequently and may be pathogenic in paraneoplastic pemphigus. J Invest Dermatol 2013; 133(7): 1785–1793. doi: 10.1038/jid.2013.65
Schepens I, Jaunin F, Begre N, et al. The protease inhibitor alpha-2-macroglobulin-like-1 is the p170 antigen recognized by paraneoplastic pemphigus autoantibodies in human. PLoS One 2010; 5(8): e12250. doi: 10.1371/journal.pone.0012250
Billet SE, Grando SA, Pittelkow MR. Paraneoplastic autoimmune multiorgan syndrome: review of the literature and support for a cytotoxic role in pathogenesis. Autoimmunity 2006; 39(7): 617–630. doi: 10.1080/08916930600972099
Reich K, Brinck U, Letschert M, et al. Graft-versus-host disease-like immunophenotype and apoptotic keratinocyte death in paraneoplastic pemphigus. Br J Dermatol 1999; 141(4): 739–746. doi: 10.1046/j.1365-2133.1999.03123.x
Cummins DL, Mimouni D, Tzu J, et al. Lichenoid paraneoplastic pemphigus in the absence of detectable antibodies. J Am Acad Dermatol 2007; 56(1): 153–159. doi: 10.1016/j.jaad.2006.06.007
Wade MS, Black MM. Paraneoplastic pemphigus: a brief update. Australas J Dermatol 2005; 46: 1–8. doi: 10.1111/j.1440-0960.2005.126_1.x
Bialy-Golan A, Brenner S, Anhalt GJ. Paraneoplastic pemphigus: oral involvement as the sole manifestation. Acta Derm Venereol 1996; 76(3): 253–254.
Lee SE, Kim SC. Paraneoplastic pemphigus. Dermatol Sin 2010; 28(1): 1–14. doi: 10.1016/S1027-8117(10)60001-8
Vassileva S, Drenovska K, Manuelyan K. Auto-immune blistering dermatoses as systemic diseases. Clin Dermatol 2014; 32(3): 364–375. doi: 10.1016/j.clindermatol.2013.11.003
Zhu X, Zhang B. Paraneoplastic pemphigus. J Dermatol 2007; 34(8): 503–511. doi: 10.1111/j.1346-8138.2007.00322.x
Lee SE, Hashimoto T, Kim SC. No mucosal involvement in a patient with paraneoplastic pemphigus associated with thymoma and myasthenia gravis. Br J Dermatol 2008; 159(4): 986–988. doi: 10.1111/j.1365-2133.2008.08763.x
Meyers SJ, Varley GA, Meisler DM, et al. Conjunctival involvement in paraneoplastic pemphigus. Am J Ophthalmol 1992; 114(5): 621–624. doi: 10.1016/S0002-9394(14)74494-0
Ng PP, Rencic A, Nousari HC. Paraneoplastic pemphigus: a refractory autoimmune mucocutaneous disease. J Cutan Med Surg 2002; 6(5): 434–437. doi: 10.1007/s10227-001-0130-x
Mutasim DF, Pelc NJ, Anhalt GJ. Paraneoplastic pemphigus. DermatolClin 1993; 11(3): 473–481.
Tankel M, Tannenbaum S, Parekh S. Paraneoplastic pemphigus presenting as an unusual bullous eruption. J Am Acad Dermatol 1993; 29(5 Pt 2): 825–858.
Sapadin AN, Anhalt GJ. Paraneoplastic pemphigus with a pemphigus vegetans-like plaque as the only cutaneous manifestation. J Am Acad Dermatol 1998; 39(5 Pt 2): 867–871. doi: 10.1016/S0190-9622(98)70368-8
Maldonado F, Pittelkow MR, Ryu JH. Constrictive bronchiolitis associated with paraneoplastic autoimmune multi-organ syndrome. Respirology 2009; 14(1): 129–133. doi: 10.1111/j.1440-1843.2008.01397.x
Joly P, Richard C, Gilbert D, et al. Sensitivity and specificity of clinical, histologic, and immunologic features in the diagnosis of paraneoplastic pemphigus. J Am Acad Dermatol 2000; 43(4): 619–626. doi: 10.1067/mjd.2000.107488
Helou J, Allbritton J, Anhalt G. Accuracy of indirect immunofluorescence in the diagnosis of paraneoplastic pemphigus. J Am Acad Dermatol 1995; 32(3): 441–447. doi: 10.1016/0190-9622(95)90066-7
Cozzani E, Dal Bello MG, Mastrogiacomo A, et al. Antidesmoplakin antibodies in pemphigus vulgaris. Br J Dermatol 2006; 154(4): 624–628. doi: 10.1111/j.1365-2133.2005.06987.x
Kazerounian S, Mahoney MG, Uitto J, et al. Envoplakin and periplakin, the paraneoplastic pemphigus antigens, are also recognized by pemphigus foliaceus auto-antibodies. J Invest Dermatol 2000; 115(3): 505–507. doi: 10.1046/j.1523-1747.2000.00088-2.x
Ishii N, Maeyama Y, Karashima T, et al. Immunoserological analyses of 55 patients with pemphigus at the Dermatological Department of Kurume University Hospital: an 11-year retrospective study (1996–2006). Int J Dermatol 2008; 47(12): 1321–1322. doi: 10.1111/j.1365-4632.2008.03712.x
Probst C, Schlumberger W, Stöcker W, et al. Development of ELISA for the specific determination of autoantibodies against envoplakin and periplakin in paraneoplastic pemphigus. Clin Chim Acta 2009; 410(1-2): 13–18. doi: 10.1016/j.cca.2009.08.022
Ishii N, Teye K, Fukuda S et al. Anti-desmocollin autoantibodies in nonclassical pemphigus. Br J Dermatol 2015 Jul; 3(1): 59–68. doi: 10.1111/bjd.13711
Hashimoto T, Amagai M, Watanabe K, et al. Characterization of paraneoplastic pemphigus autoantigens by immunoblot analysis. J Invest Dermatol 1995; 104(5): 829–834. doi: 10.1111/1523-1747.ep12607012
Camisa C, Helm TN. Paraneoplastic pemphigus is a distinct neoplasia-induced autoimmune disease. Arch Dermatol 1993; 129(7): 883–886. doi: 10.1001/archderm.1993.01680280071014
Ohzono A, Sogame R, Li X, et al. Clinical and immuno-logical findings in 104 cases of paraneoplastic pemphigus. Br J Dermatol 2015 Sep 10. doi: 10.1111/bjd.14162. [Epub ahead of print]
Hata T, Nishimoto S, Nagao K, et al. Ectopic expression of epidermal antigens renders the lung a target organ in paraneoplastic pemphigus. J Immunol 2013; 191(1): 83–90. doi: 10.4049/jimmunol.1203536
Poot AM, Diercks GF, Kramer D, et al. Laboratory diagnosis of paraneoplastic pemphigus. Br J Dermatol 2013; 169(5): 1016–1024. doi: 10.1111/bjd.12479
Dega H, Laporte JL, Joly P, et al. Paraneoplastic pemphigus associated with Hodgkin’s disease. Br J Dermatol 1998; 138(1): 196–198. doi: 10.1046/j.1365-2133.1998.02056.x
Martínez De Pablo MI, Iranzo P, et al. Paraneoplastic pemphigus associated with non-Hodgkin B-cell lymphoma and good response to prednisone. Acta Derm Venereol 2005; 85(3): 233–235.
Gergely L, Váróczy L, Vadász G, et al. Successful treatment of B cell chronic lymphocytic leukemia-associated severe paraneoplastic pemphigus with cyclosporin A. Acta Haematol 2003; 109(4): 202–205. doi: 10.1159/000070972
Williams JV, Marks JG, Billingsley EM. Use of myco-phenolate mofetil in the treatment of paraneoplastic pemphigus. Br J Dermatol 2000; 142(3): 506–508. doi: 10.1046/j.1365-2133.2000.03365.x
Hertzberg MS, Schifter M, Sullivan J, et al. Paraneoplastic pemphigus in two patients with B-cell non-Hodgkin’s lymphoma: significant responses to cyclophosphamide and prednisolone. Am J Hematol 2000; 63(2): 105–106. doi: 10.1002/(sici)1096-8652(200002)63:23.0.co;2-c
Hayag MV, Cohen JA, Kerdel FA. Immunoablative high-dose cyclophosphamide without stem cell rescue in a patient with pemphigus vulgaris. J Am Acad Dermatol 2000; 43(6): 1065–1069. doi: 10.1067/mjd.2000.110397
Tan-Lim R, Bystryn JC. Effect of plasmapheresis therapy on circulating levels of pemphigus antibodies. J Am Acad Dermatol 1990; 22(1): 35–40. doi: 10.1016/0190-9622(90)70004-2
Izaki S, Yoshizawa Y, Kitamura K, et al. Paraneoplastic pemphigus: potential therapeutic effect of plasmapheresis. Br J Dermatol 1996; 134(5): 987–989. doi: 10.1111/j.1365-2133.1996.tb06349.x
Hertl M, Zillikens D, Borradori L, et al. Recommendations for the use of rituximab (anti-CD20 antibody) in the treatment of autoimmune bullous skin diseases. J Dtsch Dermatol Ges 2008; 6(5): 366–373. doi: 10.1111/j.1610-0387.2007.06602.x
Hainsworth JD, Burris HA, Morrissey LH, et al. Rituximab monoclonal antibody as initial systemic therapy for patients with low-grade non-Hodgkin’s lymphoma. Blood 2000; 95(10): 3052–3056.
Hohwy T, Bang K, Steiniche T, et al. Alemtuzumab-induced remission of both severe paraneoplastic pemphigus and leukaemic bone marrow infiltration in a case of treatment-resistant B-cell chronic lymphocytic leukaemia. Eur J Haematol 2004; 73(3): 206–209. doi: 10.1111/j.1600-0609.2004.00280.x
Wang J, Zhu X, Li R, et al. Paraneoplastic pemphigus associated with Castleman tumor: a commonly reported subtype of paraneoplastic pemphigus in China. Arch Dermatol 2005; 141(10): 1285–1293. doi: 10.1001/archderm.141.10.1285
Dong Y, Wang M, Nong L, et al. Clinical and laboratory characterization of 114 cases of Castleman disease patients from a single centre: paraneoplastic pemphigus is an unfavourable prognostic factor. Br J Haematol 2015; 169(6): 834–842. doi: 10.1111/bjh.13378
DOI: http://dx.doi.org/10.30564/amor.v1i2.17
Refbacks
- There are currently no refbacks.
Copyright (c) 2018 Dario Didona, Biagio Didona, Antonio G Richetta, Carmen Cantisani, Elisa Moliterni, Stefano Calvieri, Giovanni Paolino

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.